NICHOLS et al. V. TABAKOFF et al. - Page 32


                                                                                0                                            

             Interference No. 104,522 Paper108                                                                               
             Nichols v. Tabakoff Page 32                                                                                     
             inventor has disclosed to others and what that disclosure means to one of ordinary skill                        

             in the art." In re Jolle -, 308 F.3d 1317, 1321, 64 USPQ2d 1901, 1904 (Fed. Cir. 2002),                         

             quoting Spero v. Ringold, 377 F.2d 652, 660, 153 USPQ 726, 732 (CCPA 1967). The                                 

             evidence must show that the inventor disclosed to others his "completed thought                                 

             expressed in such clear terms as to enable those skilled in the art" to make the                                

             invention. Coleman v. Dines, 754 F.2d 353, 359, 224 USPQ 857, 862 (Fed. Cir. 1985);                             

             Field v. Knowles, 183 F.2d 593, 600, 86 USPQ 373, 379 (CCPA 1950).                                              

                                   a. the chemical structure of a 4-urea kynurenic acid                                      
                                          derivative originated with Tabakoff                                                

             68. Initially, we note, by way of background, that Dr. Nichols testified that                                   

                    [m]y research with NMDA receptors and antagonists led to my work with                                    
                    kynurenic acid derivatives. Kynurenic acid derivatives have been shown                                   
                    to be a competitive inhibitor [sic] of glycine binding at the NMDA receptor.                             
                    Unless specifically stated otherwise, any references in this declaration to                              
                    my work in designing and synthesizing novel kynurenic acid derivatives                                   
                    involved the inventive contributions of K. Lemone Yielding ("Yielding").                                 

                    Continuing research with kynurenic acid derivatives led to the syntheses                                 
                    of novel 4-amino substituted derivatives for use as NMDA antagonists,                                    
                    such as 4-methylamino-5,7-dichloro-2-quinoline carboxylate, which                                        
                    became the subject of U.S. Patent No. 5,493,027, issued in 1996 [based                                   
                    on application 6,918, filed January 22, 1993] (previously filed as Exhibit                               
                    2015).                                                                                                   
                    [NR, pp. 25-26, IT 6, 8.]                                                                                

             69. Dr. Nichols testified that he met Larry Snell (one of the Tabakoff inventors), then                         

             a Ph.D. graduate student studying the pharmacology of NMDA receptors, while working                             

             at the University of Texas Medical Branch (NR, p. 6, $ 10; p. 26, 19).                                          

             70. Dr. Snell joined Dr. Boris Tabakoff at the University of Colorado following his                             

             Ph.D. and postdoctoral studies (NR, p. 10, 7 24; p. 26, T 10).                                                  









Page:  Previous  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  Next 

Last modified: November 3, 2007